Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1): A molecular predictor of poor survival in glioblastoma multiforme in Egyptian patients

Fawzy, Manal S.; Toraih, Eman A.; Abdallah, Hoda Y.

doi:10.1016/j.ejmhg.2016.08.003

Cited by 18 publications

(12 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All reactions included three types of control: two controls for RT reactions and NTC for real time PCR (that contains nuclease free water instead of cDNA), to confirm the absence of non-specific PCR product generation. The PCR assays were performed in a StepOne Real-Time PCR System (Applied Biosystems) as follows: 95 °C for 10 minu followed by 40 cycles of 92 °C for 15 s and 60 °C for 1 min (Fawzy et al. , 2017b).…”

Section: Methodsmentioning

confidence: 99%

Association of long non-coding RNA MIAT and MALAT1 expression profiles in peripheral blood of coronary artery disease patients with previous cardiac events

et al. 2019

Self Cite

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are implicated in various cellular and pathological processes. Two lncRNAs, myocardial infarction-associated transcript (MIAT) and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), may be involved in the pathogenesis of coronary artery disease (CAD). Here, we aimed to determine the relative circulating levels of MIAT and MALAT1 in 110 stable CAD patients and 117 controls and to correlate their levels with the clinical and laboratory data. Peripheral blood expression levels were quantified by Real-Time qPCR. The median MIAT expression level in CAD patients was significantly 12-fold higher than controls (p<0.001). Otherwise, the median MALAT1 expression level was comparable in patient and control groups. Both lncRNAs showed significantly higher relative expression levels in patients with positive history of previous cardiac ischemic events, and MIAT showed significantly higher expression in diabetic CAD patients. The area under the curve of MIAT (0.888 ± 0.02 with sensitivity 95.5% and specificity 72.7%), was significantly larger than that of MALAT1 (0.601 ± 0.04 with sensitivity 50% and specificity 63.6%) for detecting the presence of significant CAD. The current findings suggest that lncRNA MIAT could have a diagnostic significance in CAD patients. MALAT1 levels, however, are not sufficiently reliable to have much clinical use in our cases.

show abstract

Section: Methodsmentioning

confidence: 99%

Association of long non-coding RNA MIAT and MALAT1 expression profiles in peripheral blood of coronary artery disease patients with previous cardiac events

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nevertheless, previous studies reported contradictory results on the expression profile of MALAT1 in GB. Fawzy et al showed that MALAT1 expression was downregulated in Egyptian patients with GB and that lower MALAT1 expression was associated with tumor recurrence, lower OS, and shorter disease-free survival (DFS) [26]. Han et al reported that MALAT1 acts as a tumor suppressor in glioma cells by downregulation of matrix metalloproteinase-2 (MMP2) and inactivation of the in GB patients that was associated with poor response to TMZ treatment and lower survival.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas

Argadal

Mutlu

Aksoy

et al. 2019

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Primary glioblastoma (GB) is the most aggressive type of brain tumors. While mutations in isocitrate dehydrogenase (IDH) genes are frequent in secondary GBs and correlate with a better prognosis, most primary GBs are IDH wild-type. Recent studies have shown that the long noncoding RNA metastasis associated lung adenocarcinoma transcript-1 (MALAT1) is associated with aggressive tumor phenotypes in different cancers. Our aim was to clarify the prognostic significance of MALAT1 in IDH1/2 wild-type primary GB tumors. We analyzed IDH1/2 mutation status in 75 patients with primary GB by DNA sequencing. The expression of MALAT1 was detected in the 75 primary GB tissues and 5 normal brain tissues using reverse transcription quantitative PCR (RT-qPCR). The associations between MALAT1 expression, IDH1/2 mutation status, and clinicopathological variables of patients were determined. IDH1 (R132H) mutation was observed in 5/75 primary GBs. IDH2 (R172H) mutation was not detected in any of our cases. MALAT1 expression was significantly upregulated in primary GB vs. normal brain tissues (p = 0.025). Increased MALAT1 expression in IDH1/2 wild-type primary GBs correlated with patient age and tumor localization (p = 0.032 and p = 0.025, respectively). A multivariate analysis showed that high MALAT1 expression was an unfavorable prognostic factor for overall survival (p = 0.034) in IDH1/2 wild-type primary GBs. High MALAT1 expression may have a prognostic role in primary GBs independent of IDH mutations.

show abstract

“…The Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines were followed for the real-time PCR reactions. Pluripotent gene relative expressions were assessed using “Universal PCR master mix II, No UNG (2×)” (TaqMan®, Applied Biosystems, P/N 4440043), TaqMan assay (Applied Biosystems, assay ID Hs02387400_g1 for NANOG, Hs01053049_s1 for SOX2, and Hs03005111_g for OCT3/4) and compared to the endogenous control TATA box binding protein ( TBP ) (Hs00427620_m1) which has been proved in our previous work [ 24 ] to be uniformly and stably expressed with no significant difference between GBM and noncancer tissues for gene expression normalization. PCRs were done in 20 μ l total volume using “StepOne™ Real-Time PCR System (Applied Biosystems)” as previously described in details [ 25 ].…”

Section: Methodsmentioning

confidence: 99%

Longevity‐Related Gene Transcriptomic Signature in Glioblastoma Multiforme

Fawzy

Badran

Ageeli

et al. 2018

Oxidative Medicine and Cellular Longevity

Self Cite

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) (grade IV astrocytoma) has been assumed to be the most fatal type of glioma with low survival and high recurrence rates, even after prompt surgical removal and aggressive courses of treatment. Transcriptional reprogramming to stem cell-like state could explain some of the deregulated molecular signatures in GBM disease. The present study aimed to quantify the expression profiling of longevity-related transcriptional factors SOX2, OCT3/4, and NANOG to evaluate their diagnostic and performance values in high-grade gliomas. Forty-four specimens were obtained from glioblastoma patients (10 females and 34 males). Quantitative real-time polymerase chain reaction was applied for relative gene expression quantification. In silico network analysis was executed. NANOG and OCT3/4 mRNA expression levels were significantly downregulated while that of SOX2 was upregulated in cancer compared to noncancer tissues. Receiver operating characteristic curve analysis showed high diagnostic performance of NANOG and OCT3/4 than SOX2. However, the aberrant expressions of the genes studied were not associated with the prognostic variables in the current population. In conclusion, the current study highlighted the aberrant expression of certain longevity-associated transcription factors in glioblastoma multiforme which may direct the attention towards new strategies in the treatment of such lethal disease.

show abstract

Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1): A molecular predictor of poor survival in glioblastoma multiforme in Egyptian patients

Cited by 18 publications

References 53 publications

Association of long non-coding RNA MIAT and MALAT1 expression profiles in peripheral blood of coronary artery disease patients with previous cardiac events

Association of long non-coding RNA MIAT and MALAT1 expression profiles in peripheral blood of coronary artery disease patients with previous cardiac events

Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas

Longevity‐Related Gene Transcriptomic Signature in Glioblastoma Multiforme

Contact Info

Product

Resources

About